Lipid-Nanoparticle Based Genomic Medicines Market Size, Trends and Insights By Type (Liposome-based Nanoparticles, Micelle-based Nanoparticles, Lipid-Coated Nanoparticles), By Application (Cancer Treatment, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases, Others), By Therapeutic Payload (mRNA-based Therapeutics, siRNA-based Therapeutics, miRNA-based Therapeutics, Other Genomic Medicines), By End-User (Hospitals, Biopharmaceutical Companies, Research Institutes, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- Moderna Inc.
- Pfizer Inc.
- BioNTech SE
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals Inc.
- Others
Reports Description
As per the current market research conducted by the CMI Team, the global Lipid-Nanoparticle Based Genomic Medicines Market is expected to record a CAGR of 8.4% from 2023 to 2032. In 2023, the market size is projected to reach a valuation of USD 17.6 Billion. By 2032, the valuation is anticipated to reach USD 36.4 Billion.
The Lipid-Nanoparticle Based Genomic Medicines Market encompasses the development and application of advanced lipid-based nanoparticles for delivering genomic therapies. Focused on precision medicine, these technologies, pioneered by key players like Moderna and Pfizer, leverage mRNA and other genomic approaches to treat diseases at a molecular level.
The market, marked by breakthroughs in mRNA vaccines, addresses diverse therapeutic areas, including infectious diseases, oncology, and genetic disorders. Continuous innovation, strategic collaborations, and regulatory advancements characterize this evolving landscape, positioning lipid-nanoparticle based genomic medicines as transformative solutions in the era of personalized healthcare.
Lipid-Nanoparticle Based Genomic Medicines Market – Significant Growth Factors
The Lipid-Nanoparticle Based Genomic Medicines Market presents significant growth opportunities due to several factors:
- Advancements in Nanotechnology: Ongoing innovations in nanotechnology, particularly lipid-based nanoparticles, drive the development of precise and efficient delivery systems for genomic medicines, enhancing their therapeutic efficacy.
- Expanding Genomic Therapies: The growing application of genomic medicines, especially mRNA-based therapies, for a wide range of diseases including infectious diseases, cancer, and genetic disorders, fuels the demand for lipid-nanoparticle delivery platforms.
- Increased Investment in Research and Development: Rising investments in R&D by pharmaceutical companies and biotech firms contribute to the discovery and development of novel lipid-nanoparticle based genomic medicines, accelerating market growth.
- Strategic Collaborations and Partnerships: Collaborations among key industry players, research institutions, and biopharmaceutical companies foster synergies, pooling resources, and expertise and accelerating the development and commercialization of lipid-nanoparticle based genomic therapies.
- Expansion into Rare Diseases: An opportunity lies in the expansion of lipid-nanoparticle based genomic medicines into the treatment of rare diseases, addressing unmet medical needs and offering potential breakthroughs for patients with genetic disorders.
- Customized Therapies for Precision Medicine: The opportunity to tailor lipid-nanoparticle based genomic medicines for precision medicine applications, providing individualized therapies based on genetic profiles, holds promise for optimizing treatment outcomes and patient responses.
Lipid-Nanoparticle Based Genomic Medicines Market – Mergers and Acquisitions
The Lipid-Nanoparticle Based Genomic Medicines Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Lipid-Nanoparticle Based Genomic Medicines Market include:
- In 2022, Evonik Industries AG collaborates with the U.S. government to establish a lipid-based production center for mRNA-based products. The U.S. government, via BARDA, provides up to USD 150 million in funding for this initiative, emphasizing support for advancing crucial biomedical research and development.
- In 2021, Gattefossé introduced three new lipid excipients—Labrafac MC60, Gelucire, and Emulfree Duo—to diversify its product portfolio and offer distinct customer solutions. This expansion reflects Gattefossé’s commitment to providing innovative lipid-based ingredients for various applications in the pharmaceutical and cosmetic industries.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Lipid-Nanoparticle Based Genomic Medicines Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
COMPARATIVE ANALYSIS OF THE RELATED MARKET
| Lipid-Nanoparticle Based Genomic Medicines Market | Bone and Joint Health Supplement Market | Fungal Infection Diagnosis Market |
| CAGR 8.4% (Approx) | CAGR 9.5% (Approx) | CAGR 4.1% (Approx) |
| USD 36.4 Billion by 2032 | USD 17.17 Billion by 2032 | USD 21.5 Billion by 2032 |
Lipid-Nanoparticle Based Genomic Medicines Market – Significant Threats
The Lipid-Nanoparticle Based Genomic Medicines Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
- Regulatory Challenges: Stringent regulatory requirements and evolving guidelines pose a significant threat. Compliance challenges and uncertainties in regulatory processes may hinder the timely approval of lipid-nanoparticle based genomic medicines, impacting market access.
- Safety Concerns and Side Effects: Potential safety issues and unforeseen side effects associated with lipid-nanoparticle delivery systems or genomic medicines themselves can lead to setbacks, eroding trust among healthcare providers, patients, and regulators.
- Competitive Landscape and Intellectual Property Risks: Intense competition and the risk of intellectual property disputes pose threats. Companies face challenges protecting proprietary technologies, and legal battles may hinder market entry and product development.
- High Development Costs and Market Access Barriers: The high costs of research, development, and production for lipid-nanoparticle based genomic medicines pose financial challenges. Market access barriers, including reimbursement issues and pricing pressures, may hinder the commercial success of these innovative therapies.
Report Scope
| Feature of the Report | Details |
| Market Size in 2023 | USD 17.6 Billion |
| Projected Market Size in 2032 | USD 36.4 Billion |
| Market Size in 2022 | USD 16.2 Billion |
| CAGR Growth Rate | 8.4% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Type, Application, Therapeutic Payload, End-User and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Category-Wise Insights
By Type
- Liposome-based Nanoparticles: Liposome-based nanoparticles encapsulate genomic medicines, facilitating targeted delivery. Trends include enhanced stability and increased encapsulation efficiency, improving drug delivery precision. These nanoparticles are prominent in mRNA vaccines.
- Micelle-based Nanoparticles: Micelle-based nanoparticles use amphiphilic molecules to form micelles, aiding genomic medicine delivery. Trends focus on improved loading capacity and controlled release, enhancing therapeutic efficacy for diverse applications, notably in cancer treatments.
- Lipid-Coated Nanoparticles: Lipid-coated nanoparticles involve a core coated with lipids for genomic medicine encapsulation. Trends include customization for specific drug release profiles, and promoting controlled and sustained release in precision medicine applications.
By Application
- Cancer Treatment: Lipid-nanoparticle based genomic medicines in cancer treatment involve delivering mRNA therapies for precision oncology. Trends include personalized cancer vaccines, targeted therapies, and advances in lipid-nanoparticle formulations to enhance drug delivery, improving treatment outcomes.
- Infectious Diseases: In treating infectious diseases, lipid-nanoparticle based genomic medicines focus on mRNA vaccines. Trends encompass rapid vaccine development, pandemic response readiness, and ongoing advancements in mRNA technology for infectious disease prevention.
- Genetic Disorders: Addressing genetic disorders, lipid-nanoparticle based genomic medicines deliver mRNA for targeted gene therapies. Trends involve expanding applications for rare diseases, personalized treatments, and breakthroughs in treating specific genetic mutations.
- Cardiovascular Diseases: In cardiovascular diseases, lipid-nanoparticle based genomic medicines aim to target specific genetic factors contributing to cardiovascular conditions. Trends include RNA-based therapies for cardiovascular disorders, with a focus on precision medicine and personalized treatment approaches.
- Others: Lipid-nanoparticle based genomic medicines find diverse applications beyond the mentioned categories. Trends encompass innovative applications in neurodegenerative disorders, autoimmune diseases, and emerging therapeutic areas, reflecting the versatility and evolving nature of genomic medicine applications.
By Therapeutic Payload
- mRNA-based Therapeutics: mRNA-based therapeutics involve utilizing lipid-nanoparticles for the delivery of messenger RNA, directing cells to produce specific proteins. Trends include mRNA vaccine breakthroughs, notably in infectious diseases and cancer, showcasing the potential for personalized medicine through targeted protein synthesis.
- siRNA-based Therapeutics: siRNA-based therapeutics employ lipid-nanoparticles to deliver small interfering RNA, silencing targeted genes. Trends focus on applications in oncology, neurodegenerative diseases, and viral infections, demonstrating the potential for precise gene regulation and therapeutic intervention.
- miRNA-based Therapeutics: miRNA-based therapeutics leverage lipid-nanoparticles to deliver microRNA, influencing gene expression. Trends highlight applications in cancer, cardiovascular diseases, and metabolic disorders, indicating the potential for regulating intricate biological processes and developing targeted treatments.
- Other Genomic Medicines: Other genomic medicines encompass a variety of lipid-nanoparticle-delivered therapies beyond mRNA, siRNA, and miRNA. Trends involve expanding applications into genetic disorders, rare diseases, and innovative approaches, broadening the scope of lipid-nanoparticle based genomic medicine interventions.
By End User
- Hospitals: Hospitals, as end users, integrate lipid-nanoparticle based genomic medicines into patient care. They leverage these therapies for precision treatment, especially in oncology and infectious diseases, enhancing therapeutic outcomes and contributing to personalized medicine trends.
- Biopharmaceutical Companies: Biopharmaceutical companies drive innovation in lipid-nanoparticle based genomic medicines. Focused on drug development, they conduct clinical trials, optimize formulations, and bring novel therapies to market, shaping the industry’s competitive landscape.
- Research Institutes: Research institutes play a pivotal role in advancing lipid-nanoparticle technologies. They conduct foundational research, exploring new applications and refining delivery systems, contributing to the continual evolution of genomic medicines.
- Others: Other end users, including specialty clinics and healthcare providers, adopt lipid-nanoparticle based genomic medicines for diverse applications. This segment reflects the broader integration of these therapies into various healthcare settings beyond traditional hospitals and research institutions.
Lipid-Nanoparticle Based Genomic Medicines Market – Regional Analysis
The Lipid-Nanoparticle Based Genomic Medicines Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:
- North America: In North America, the trend centers on the widespread adoption of mRNA-based vaccines and therapeutics. Robust investments in biopharmaceutical research drive innovation, with a focus on expanding lipid-nanoparticle genomic medicines into areas like neurodegenerative diseases. Regulatory support and collaborations between academia and industry contribute to the region’s leadership in genomic medicine development.
- Europe: Europe emphasizes sustainability in lipid-nanoparticle technologies. Trends include research on eco-friendly lipid formulations, and addressing environmental concerns. The region also witnesses collaborative efforts in precision oncology, with a focus on personalized genomic therapies and advancements in lipid-based drug delivery systems.
- Asia-Pacific: Asia-Pacific experiences a surge in research collaborations, particularly in emerging markets. Trends involve the development of affordable lipid-nanoparticle technologies for wider accessibility. The region sees increased focus on addressing infectious diseases through mRNA-based vaccines, reflecting efforts to enhance public health preparedness.
- LAMEA (Latin America, Middle East, and Africa): LAMEA trends revolve around the application of lipid-nanoparticle genomic medicines in tackling regional health challenges. Initiatives include the development of lipid-based therapeutics for prevalent diseases, emphasizing affordability and accessibility. Collaborations with global partners contribute to the region’s integration into the evolving landscape of genomic medicine.
Competitive Landscape – Lipid-Nanoparticle Based Genomic Medicines Market
The Lipid-Nanoparticle Based Genomic Medicines Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:
- Moderna Inc.
- Pfizer Inc.
- BioNTech SE
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals Inc.
- CureVac N.V.
- Lipocalyx
- Acuitas Therapeutics
- Precision NanoSystems Inc.
- IONTAS Limited
- Genevant Sciences
- Roche Holding AG
- Alnylam Pharmaceuticals Inc.
- SiO2 Materials Science
- Ethris GmbH
- Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
New entrants like Lipocalyx and IONTAS demonstrate innovation in lipid-nanoparticle-based genomic medicines, introducing novel delivery technologies. Key players dominating include Moderna, Pfizer, and BioNTech, driving market leadership through groundbreaking mRNA vaccines. These pioneers leverage extensive R&D investments, strategic collaborations, and regulatory successes, solidifying their position.
Their focus on expanding applications, such as personalized medicine and oncology treatments, showcases sustained commitment to advancing genomic medicine. Collaborative efforts with research institutes and biopharmaceutical companies contribute to the industry’s transformative evolution, positioning these key players at the forefront of lipid-nanoparticle genomic medicine development.
The Lipid-Nanoparticle Based Genomic Medicines Market is segmented as follows:
By Type
- Liposome-based Nanoparticles
- Micelle-based Nanoparticles
- Lipid-Coated Nanoparticles
By Application
- Cancer Treatment
- Infectious Diseases
- Genetic Disorders
- Cardiovascular Diseases
- Others
By Therapeutic Payload
- mRNA-based Therapeutics
- siRNA-based Therapeutics
- miRNA-based Therapeutics
- Other Genomic Medicines
By End-User
- Hospitals
- Biopharmaceutical Companies
- Research Institutes
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global Lipid-Nanoparticle Based Genomic Medicines Market, (2024 – 2033) (USD Billion)
- 2.2 Global Lipid-Nanoparticle Based Genomic Medicines Market: snapshot
- Chapter 3. Global Lipid-Nanoparticle Based Genomic Medicines Market – Industry Analysis
- 3.1 Lipid-Nanoparticle Based Genomic Medicines Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Advancements in Nanotechnology
- 3.2.2 Expanding Genomic Therapies
- 3.2.3 Increased Investment in Research and Development
- 3.2.4 Strategic Collaborations and Partnerships
- 3.2.5 Expansion into Rare Diseases
- 3.2.6 Customized Therapies for Precision Medicine.
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Therapeutic Payload
- 3.7.4 Market Attractiveness Analysis By End-User
- Chapter 4. Global Lipid-Nanoparticle Based Genomic Medicines Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Lipid-Nanoparticle Based Genomic Medicines Market: Company Market Share, 2022
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, collaboration, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Lipid-Nanoparticle Based Genomic Medicines Market – Type Analysis
- 5.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Overview: By Type
- 5.1.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Share, By Type, 2022 and – 2033
- 5.2 Liposome-based Nanoparticles
- 5.2.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Liposome-based Nanoparticles, 2024 – 2033 (USD Billion)
- 5.3 Micelle-based Nanoparticles
- 5.3.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Micelle-based Nanoparticles, 2024 – 2033 (USD Billion)
- 5.4 Lipid-Coated Nanoparticles
- 5.4.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Lipid-Coated Nanoparticles, 2024 – 2033 (USD Billion)
- 5.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Overview: By Type
- Chapter 6. Global Lipid-Nanoparticle Based Genomic Medicines Market – Application Analysis
- 6.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Overview: By Application
- 6.1.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Share, By Application, 2022 and – 2033
- 6.2 Cancer Treatment
- 6.2.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Cancer Treatment, 2024 – 2033 (USD Billion)
- 6.3 Infectious Diseases
- 6.3.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Infectious Diseases, 2024 – 2033 (USD Billion)
- 6.4 Genetic Disorders
- 6.4.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Genetic Disorders, 2024 – 2033 (USD Billion)
- 6.5 Cardiovascular Diseases
- 6.5.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Cardiovascular Diseases, 2024 – 2033 (USD Billion)
- 6.6 Others
- 6.6.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Others, 2024 – 2033 (USD Billion)
- 6.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Overview: By Application
- Chapter 7. Global Lipid-Nanoparticle Based Genomic Medicines Market – Therapeutic Payload Analysis
- 7.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Overview: By Therapeutic Payload
- 7.1.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Share, By Therapeutic Payload, 2022 and – 2033
- 7.2 mRNA-based Therapeutics
- 7.2.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by mRNA-based Therapeutics, 2024 – 2033 (USD Billion)
- 7.3 siRNA-based Therapeutics
- 7.3.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by siRNA-based Therapeutics, 2024 – 2033 (USD Billion)
- 7.4 miRNA-based Therapeutics
- 7.4.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by miRNA-based Therapeutics, 2024 – 2033 (USD Billion)
- 7.5 Other Genomic Medicines
- 7.5.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Other Genomic Medicines, 2024 – 2033 (USD Billion)
- 7.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Overview: By Therapeutic Payload
- Chapter 8. Global Lipid-Nanoparticle Based Genomic Medicines Market – End-User Analysis
- 8.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Overview: By End-User
- 8.1.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Share, By End-User, 2022 and – 2033
- 8.2 Hospitals
- 8.2.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Hospitals, 2024 – 2033 (USD Billion)
- 8.3 Biopharmaceutical Companies
- 8.3.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Biopharmaceutical Companies, 2024 – 2033 (USD Billion)
- 8.4 Research Institutes
- 8.4.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Research Institutes, 2024 – 2033 (USD Billion)
- 8.5 Others
- 8.5.1 Global Lipid-Nanoparticle Based Genomic Medicines Market by Others, 2024 – 2033 (USD Billion)
- 8.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Overview: By End-User
- Chapter 9. Lipid-Nanoparticle Based Genomic Medicines Market – Regional Analysis
- 9.1 Global Lipid-Nanoparticle Based Genomic Medicines Market Regional Overview
- 9.2 Global Lipid-Nanoparticle Based Genomic Medicines Market Share, by Region, 2022 & – 2033 (USD Billion)
- 9.3. North America
- 9.3.1 North America Lipid-Nanoparticle Based Genomic Medicines Market, 2024 – 2033 (USD Billion)
- 9.3.1.1 North America Lipid-Nanoparticle Based Genomic Medicines Market, by Country, 2024 – 2033 (USD Billion)
- 9.3.1 North America Lipid-Nanoparticle Based Genomic Medicines Market, 2024 – 2033 (USD Billion)
- 9.4 North America Lipid-Nanoparticle Based Genomic Medicines Market, by Type, 2024 – 2033
- 9.4.1 North America Lipid-Nanoparticle Based Genomic Medicines Market, by Type, 2024 – 2033 (USD Billion)
- 9.5 North America Lipid-Nanoparticle Based Genomic Medicines Market, by Application, 2024 – 2033
- 9.5.1 North America Lipid-Nanoparticle Based Genomic Medicines Market, by Application, 2024 – 2033 (USD Billion)
- 9.6 North America Lipid-Nanoparticle Based Genomic Medicines Market, by Therapeutic Payload, 2024 – 2033
- 9.6.1 North America Lipid-Nanoparticle Based Genomic Medicines Market, by Therapeutic Payload, 2024 – 2033 (USD Billion)
- 9.7 North America Lipid-Nanoparticle Based Genomic Medicines Market, by End-User, 2024 – 2033
- 9.7.1 North America Lipid-Nanoparticle Based Genomic Medicines Market, by End-User, 2024 – 2033 (USD Billion)
- 9.8. Europe
- 9.8.1 Europe Lipid-Nanoparticle Based Genomic Medicines Market, 2024 – 2033 (USD Billion)
- 9.8.1.1 Europe Lipid-Nanoparticle Based Genomic Medicines Market, by Country, 2024 – 2033 (USD Billion)
- 9.8.1 Europe Lipid-Nanoparticle Based Genomic Medicines Market, 2024 – 2033 (USD Billion)
- 9.9 Europe Lipid-Nanoparticle Based Genomic Medicines Market, by Type, 2024 – 2033
- 9.9.1 Europe Lipid-Nanoparticle Based Genomic Medicines Market, by Type, 2024 – 2033 (USD Billion)
- 9.10 Europe Lipid-Nanoparticle Based Genomic Medicines Market, by Application, 2024 – 2033
- 9.10.1 Europe Lipid-Nanoparticle Based Genomic Medicines Market, by Application, 2024 – 2033 (USD Billion)
- 9.11 Europe Lipid-Nanoparticle Based Genomic Medicines Market, by Therapeutic Payload, 2024 – 2033
- 9.11.1 Europe Lipid-Nanoparticle Based Genomic Medicines Market, by Therapeutic Payload, 2024 – 2033 (USD Billion)
- 9.12 Europe Lipid-Nanoparticle Based Genomic Medicines Market, by End-User, 2024 – 2033
- 9.12.1 Europe Lipid-Nanoparticle Based Genomic Medicines Market, by End-User, 2024 – 2033 (USD Billion)
- 9.13. Asia Pacific
- 9.13.1 Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market, 2024 – 2033 (USD Billion)
- 9.13.1.1 Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market, by Country, 2024 – 2033 (USD Billion)
- 9.13.1 Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market, 2024 – 2033 (USD Billion)
- 9.14 Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market, by Type, 2024 – 2033
- 9.14.1 Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market, by Type, 2024 – 2033 (USD Billion)
- 9.15 Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market, by Application, 2024 – 2033
- 9.15.1 Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market, by Application, 2024 – 2033 (USD Billion)
- 9.16 Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market, by Therapeutic Payload, 2024 – 2033
- 9.16.1 Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market, by Therapeutic Payload, 2024 – 2033 (USD Billion)
- 9.17 Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market, by End-User, 2024 – 2033
- 9.17.1 Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market, by End-User, 2024 – 2033 (USD Billion)
- 9.18. Latin America
- 9.18.1 Latin America Lipid-Nanoparticle Based Genomic Medicines Market, 2024 – 2033 (USD Billion)
- 9.18.1.1 Latin America Lipid-Nanoparticle Based Genomic Medicines Market, by Country, 2024 – 2033 (USD Billion)
- 9.18.1 Latin America Lipid-Nanoparticle Based Genomic Medicines Market, 2024 – 2033 (USD Billion)
- 9.19 Latin America Lipid-Nanoparticle Based Genomic Medicines Market, by Type, 2024 – 2033
- 9.19.1 Latin America Lipid-Nanoparticle Based Genomic Medicines Market, by Type, 2024 – 2033 (USD Billion)
- 9.20 Latin America Lipid-Nanoparticle Based Genomic Medicines Market, by Application, 2024 – 2033
- 9.20.1 Latin America Lipid-Nanoparticle Based Genomic Medicines Market, by Application, 2024 – 2033 (USD Billion)
- 9.21 Latin America Lipid-Nanoparticle Based Genomic Medicines Market, by Therapeutic Payload, 2024 – 2033
- 9.21.1 Latin America Lipid-Nanoparticle Based Genomic Medicines Market, by Therapeutic Payload, 2024 – 2033 (USD Billion)
- 9.22 Latin America Lipid-Nanoparticle Based Genomic Medicines Market, by End-User, 2024 – 2033
- 9.22.1 Latin America Lipid-Nanoparticle Based Genomic Medicines Market, by End-User, 2024 – 2033 (USD Billion)
- 9.23. The Middle-East and Africa
- 9.23.1 The Middle-East and Africa Lipid-Nanoparticle Based Genomic Medicines Market, 2024 – 2033 (USD Billion)
- 9.23.1.1 The Middle-East and Africa Lipid-Nanoparticle Based Genomic Medicines Market, by Country, 2024 – 2033 (USD Billion)
- 9.23.1 The Middle-East and Africa Lipid-Nanoparticle Based Genomic Medicines Market, 2024 – 2033 (USD Billion)
- 9.24 The Middle-East and Africa Lipid-Nanoparticle Based Genomic Medicines Market, by Type, 2024 – 2033
- 9.24.1 The Middle-East and Africa Lipid-Nanoparticle Based Genomic Medicines Market, by Type, 2024 – 2033 (USD Billion)
- 9.25 The Middle-East and Africa Lipid-Nanoparticle Based Genomic Medicines Market, by Application, 2024 – 2033
- 9.25.1 The Middle-East and Africa Lipid-Nanoparticle Based Genomic Medicines Market, by Application, 2024 – 2033 (USD Billion)
- 9.26 The Middle-East and Africa Lipid-Nanoparticle Based Genomic Medicines Market, by Therapeutic Payload, 2024 – 2033
- 9.26.1 The Middle-East and Africa Lipid-Nanoparticle Based Genomic Medicines Market, by Therapeutic Payload, 2024 – 2033 (USD Billion)
- 9.27 The Middle-East and Africa Lipid-Nanoparticle Based Genomic Medicines Market, by End-User, 2024 – 2033
- 9.27.1 The Middle-East and Africa Lipid-Nanoparticle Based Genomic Medicines Market, by End-User, 2024 – 2033 (USD Billion)
- Chapter 10. Company Profiles
- 10.1 Moderna Inc.
- 10.1.1 Overview
- 10.1.2 Financials
- 10.1.3 Product Portfolio
- 10.1.4 Business Strategy
- 10.1.5 Recent Developments
- 10.2 Pfizer Inc.
- 10.2.1 Overview
- 10.2.2 Financials
- 10.2.3 Product Portfolio
- 10.2.4 Business Strategy
- 10.2.5 Recent Developments
- 10.3 BioNTech SE
- 10.3.1 Overview
- 10.3.2 Financials
- 10.3.3 Product Portfolio
- 10.3.4 Business Strategy
- 10.3.5 Recent Developments
- 10.4 Arbutus Biopharma Corporation
- 10.4.1 Overview
- 10.4.2 Financials
- 10.4.3 Product Portfolio
- 10.4.4 Business Strategy
- 10.4.5 Recent Developments
- 10.5 Arrowhead Pharmaceuticals Inc.
- 10.5.1 Overview
- 10.5.2 Financials
- 10.5.3 Product Portfolio
- 10.5.4 Business Strategy
- 10.5.5 Recent Developments
- 10.6 CureVac N.V.
- 10.6.1 Overview
- 10.6.2 Financials
- 10.6.3 Product Portfolio
- 10.6.4 Business Strategy
- 10.6.5 Recent Developments
- 10.7 Lipocalyx
- 10.7.1 Overview
- 10.7.2 Financials
- 10.7.3 Product Portfolio
- 10.7.4 Business Strategy
- 10.7.5 Recent Developments
- 10.8 Acuitas Therapeutics
- 10.8.1 Overview
- 10.8.2 Financials
- 10.8.3 Product Portfolio
- 10.8.4 Business Strategy
- 10.8.5 Recent Developments
- 10.9 Precision NanoSystems Inc.
- 10.9.1 Overview
- 10.9.2 Financials
- 10.9.3 Product Portfolio
- 10.9.4 Business Strategy
- 10.9.5 Recent Developments
- 10.10 IONTAS Limited
- 10.10.1 Overview
- 10.10.2 Financials
- 10.10.3 Product Portfolio
- 10.10.4 Business Strategy
- 10.10.5 Recent Developments
- 10.11 Genevant Sciences
- 10.11.1 Overview
- 10.11.2 Financials
- 10.11.3 Product Portfolio
- 10.11.4 Business Strategy
- 10.11.5 Recent Developments
- 10.12 Roche Holding AG
- 10.12.1 Overview
- 10.12.2 Financials
- 10.12.3 Product Portfolio
- 10.12.4 Business Strategy
- 10.12.5 Recent Developments
- 10.13 Alnylam Pharmaceuticals Inc.
- 10.13.1 Overview
- 10.13.2 Financials
- 10.13.3 Product Portfolio
- 10.13.4 Business Strategy
- 10.13.5 Recent Developments
- 10.14 SiO2 Materials Science
- 10.14.1 Overview
- 10.14.2 Financials
- 10.14.3 Product Portfolio
- 10.14.4 Business Strategy
- 10.14.5 Recent Developments
- 10.15 Ethris GmbH
- 10.15.1 Overview
- 10.15.2 Financials
- 10.15.3 Product Portfolio
- 10.15.4 Business Strategy
- 10.15.5 Recent Developments
- 10.16 Others.
- 10.16.1 Overview
- 10.16.2 Financials
- 10.16.3 Product Portfolio
- 10.16.4 Business Strategy
- 10.16.5 Recent Developments
- 10.1 Moderna Inc.
List Of Figures
Figures No 1 to 34
List Of Tables
Tables No 1 to 102
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2032
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- Moderna Inc.
- Pfizer Inc.
- BioNTech SE
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals Inc.
- CureVac N.V.
- Lipocalyx
- Acuitas Therapeutics
- Precision NanoSystems Inc.
- IONTAS Limited
- Genevant Sciences
- Roche Holding AG
- Alnylam Pharmaceuticals Inc.
- SiO2 Materials Science
- Ethris GmbH
- Others
FAQs
The key factors driving the Market are Advancements in Nanotechnology, Expanding Genomic Therapies, Increased Investment in Research and Development, Strategic Collaborations and Partnerships, Expansion into Rare Diseases And Customized Therapies for Precision Medicine.
The “Liposome-based Nanoparticles” category dominated the market in 2022.
The key players in the market are Moderna Inc., Pfizer Inc., BioNTech SE, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., CureVac N.V., Lipocalyx, Acuitas Therapeutics, Precision NanoSystems Inc., IONTAS Limited, Genevant Sciences, Roche Holding AG, Alnylam Pharmaceuticals Inc., SiO2 Materials Science, Ethris GmbH, Others.
“North America” had the largest share in the Lipid-Nanoparticle Based Genomic Medicines Market.
The global market is projected to grow at a CAGR of 8.4% during the forecast period, 2023-2032.
The Lipid-Nanoparticle Based Genomic Medicines Market size was valued at USD 17.6 Billion in 2023.